1. Home
  2. ALAR vs TCRX Comparison

ALAR vs TCRX Comparison

Compare ALAR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$6.30

Market Cap

58.8M

Sector

Technology

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
TCRX
Founded
2013
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
63.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ALAR
TCRX
Price
$6.30
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$14.00
$7.00
AVG Volume (30 Days)
39.3K
563.7K
Earning Date
03-19-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
$33.30
N/A
Revenue Next Year
$30.53
$19.81
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
266.65
52 Week Low
$5.45
$0.88
52 Week High
$18.00
$2.57

Technical Indicators

Market Signals
Indicator
ALAR
TCRX
Relative Strength Index (RSI) 43.10 48.19
Support Level N/A $0.90
Resistance Level $7.76 $1.24
Average True Range (ATR) 0.44 0.07
MACD -0.04 -0.01
Stochastic Oscillator 30.77 47.92

Price Performance

Historical Comparison
ALAR
TCRX

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: